1535P - Multimodality therapy in mesothelioma: an epidemiological and effectiveness analysis

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Anticancer agents
Mesothelioma
Surgical oncology
Therapy
Biological therapy
Radiation oncology
Presenter mario Damiano
Authors M.A. Damiano1, A.K. Patané2, M. Chacon1, R. Chacon1, V. Vilchez1, A. Rosales2, A. Falco1, C. Poleri3, M. Rosenberg2, C. Martín1
  • 1Clinical Oncology, Instituto Alexander Fleming, 1426 - buenos aires/AR
  • 2Surgical Oncology, Instituto Alexander Fleming, 1426 - buenos aires/AR
  • 3Patology, Hospital Ferrer, 1426 - buenos aires/AR

Abstract

Introduction

Malignant pleural mesothelioma (MPM) is a rare and aggressive disease arising from the pleural mesothelium, with a reported survival (OS) of less than 12 months. However, patients with early-stage disease and good-performance status are suitable for multimodality ther¬apy (MT) involving surgery, radiotherapy (PORT), and chemotherapy.

Objective

Epidemiological description and analysis of effectiveness in patients with MPM who performed MT. Methods Retrospective study of patients treated by multimodality therapy between April 1990 and April 2011 in three institutions from Argentina.

Results

Of 110 patients, 24 (22%) went to MT. Median (Md) follow-up of 21 months (2-139). Of 21 patients with complete data, 90.5% were epithelioid. 67% male, Md age 54, 95% PS 0, 43% smokers, mean of 7.6 packs/year, 29% had contact with asbestos. 60% presented with chest pain or pleural effusion, 3 month (R: 0-38) Md time to diagnosis. 60% in the right pleura. Treatment: 90.5% extrapleural pneumonectomy, 9.5% pleurectomy/decortications, by single surgical team 92%. Perioperative mortality 8%, morbidity 63%, 32% bleeding complications (32%). 52% T3N0M0 postoperative staging. 15 performed neoadjuvant, 3 adjuvant chemotherapy and 10 PORT. 67% received pemetrexed associated with platinum. 57% relapse after MT, 80% locoregional, 80% performed chemotherapy. Md disease free survival (DFS) 20.7 months (95% CI 8-46). OS 34.3 months (95% CI 17-43).

Conclusions

Epidemiological and efficiency data obtained are similar to reported series. The present work shows that MT achieves higher DFS and OS than those obtained with other treatments that do not include surgery.

Disclosure

All authors have declared no conflicts of interest.